March 27th 2025
The April issue covers atopic dermatitis, highlighting primary care’s role in early diagnosis, key updates from recent conferences, and more.
March 26th 2025
Your daily dose of the clinical news you may have missed.
March 25th 2025
March 21st 2025
Nearly 1 in 10 US adults have eczema, with 18% experiencing multiple eczema conditions, researchers from the National Eczema Association reported.
March 19th 2025
7 Drugs Approved for Primary Care: Q4 2024
An oral antibiotic for drug-resistant UTIs, a long-awaited therapy for congenital adrenal hyperplasia, and more.
Tapinarof 1% Cream Significantly Improves Patient Reported Outcomes, Including Family QoL, in Atopic Dermatitis
Tapinarof 1% cream when used as topical monotherapy led to statistically significant and sustained improvements in QoL, sleep, and other PROs across age groups.
Self-Reported Symptoms of Topical Steroid Withdrawal Identified in Study of Atopic Dermatitis
There are no diagnostic criteria for topical steroid withdrawal but patients describe and discuss it on social media. Study authors tapped a deep source of information.
New Study Suggests Patient Benefit Index Complements Traditional Psoriasis Outcome Measures
Findings showed that improved skin clearance and reduced anxiety and depression significantly influenced perceived patient benefit.
Atopic Dermatitis pipeline: IND Application Cleared by FDA for Novel Monoclonal Antibody OX40 Antagonist
Early proof-of-concept phase 1a data from the trial is anticipated in the third quarter of 2025.
Phase 2b Clinical Trial of Rezpegaldesleukin in Atopic Dermatitis Achieves Target Enrollment
Nektar Therapeutics announced the milestone in its clinical program to evaluate the IL-2 receptor agonist, a potential first-in-class treatment for the chronic condition.
Inmagene Announces Favorable Topline Efficacy and Safety Results for IMG-007 in Atopic Dermatitis
Intravenous IMG-007 at study weeks 0, 2, and 4 led to a mean reduction in EASI of 77% as early as week 4; more than half of participants reached EASI-75 at week 16.
Dermatologist Mona Shahriari, MD, Relies on Primary Care Colleagues as First-Line Prescribers for AD
Not all atopic dermatitis requires treatment by a specialist, says this dermatologist, and she collaborates regularly with her primary care colleagues.